

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58961 A1

(51) International Patent Classification⁷: **C08B 37/08, A61K 9/36**

(21) International Application Number: **PCT/EP01/01239**

(22) International Filing Date: 6 February 2001 (06.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
FI2000A000020 8 February 2000 (08.02.2000) IT

(71) Applicant (for all designated States except US): **S.F.I.R. SOCIETA' FONDIARIA INDUSTRIALE ROMAGNOLA S.P.A.** [IT/IT]; Via Benedetto Croce, 7, I-47023 Cesena (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRATINI, Luigi** [IT/IT]; Via Cisieri, 19, I-50142 Firenze (IT). **MELDOLI, Maurizio** [IT/IT]; Via Quattordici, 14, I-47023 Cesena (IT).

(74) Agent: **GERVASI, Gemma**; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **GELS OF HYALURONIC ACID CROSS-LINKED WITH BI-FUNCTIONAL L-AMINOACIDS OR L-AMINOESTERS OR MIXTURES THEREOF**

(57) Abstract: Gels consisting of hyaluronic acid cross-linked with bi-functional L-aminoacids or L-aminoesters or mixtures thereof are described.

WO 01/58961 A1


GELS OF HYALURONIC ACID CROSS-LINKED WITH BI-FUNCTIONAL L-AMINOACIDS OR L-AMINOESTERS OR MIXTURES THEREOF

Field of the invention

The present invention refers to gels insoluble in water consisting of hyaluronic acid
 5 cross-linked with bi-functional L-aminoacids, L-aminoesters or their mixtures, to a process for their preparation and to their use in the pharmaceutical, cosmetic and medical fields.

State of the art

Hyaluronic acid is a mucopolysaccharide consisting of alternated units of D-glucuronic acid and N-acetyl-glucosamine, bound together by β 1-3 and β 1-4
 10 bindings (1).



(1)

20

Hyaluronic acid is found in nature in the synovial liquid of articular joints, in the vitreous humor of eyes, in the umbilical cord and in the connective tissues; can be obtained by extraction from animal tissues like cockscombs or umbilical
 cordons, or can be recovered from the fermenting broths of specific Streptococci.

25 The development of biotechnology allowed the optimisation and improvement of the last described method of production of hyaluronic acid (recovering from fermentation broths) and is nowadays the one considered the most simple and rewarding.

The essential role played by hyaluronic acid in the human body is due to the
 30 peculiar viscoelastic, lubricant and hydrophilic characteristics of its aqueous solutions.

The applications of hyaluronic acid in various fields, surgical, pharmacological or

more generally biomedical, are widely described in literature, see for example: Balazs et al. "Hyaluronan Biomaterials: Medical Applications", *Handbook of Biomaterials and Applications*, ed. DL Wise et al., 1995, 2719-2741; US - 5,559,104, 1996; Pape, Balazs, *Ophthalmology*, 87, No. 7, 1980; Iwata, *Clin. Orthop.*, 289, 285-291; 1993; US - 5,128,326; US - 4,500,676; US - 5,840,046; 5 US - 5,795, 584; US - 6,010,692; US - 5,658,331.

Moreover a wide literature describes various compounds obtained by cross-linking hyaluronic acid with, for example, formaldehyde (Balazs, U.S. Pat. 4,713,448, 1987), divinyl sulphone (Balazs, U.S. Pat. 4,582,865, 1986), aziridine, alcohols 10 (Della Valle, U.S. Pat. 4,851,521, 1989) and mono-functional aminoacids (Hamilton, U.S. Pat. 4,937,270, 1990).

As it can be seen from the above said, hyaluronic acid can be chemically modified in order to modify its characteristics and obtain products suitable for various applications.

15 It is therefore evident the importance of making available new compounds capable of widening and improving the use of hyaluronic acid in the known or in new fields.

Detailed description of the invention

The present invention refers to gels insoluble in water prepared by cross-linking hyaluronic acid with bi-functional L-aminoacids or L-aminoesters or their mixtures.

20 The introduction of little biocompatible molecules as the α L-aminoacids in the hyaluronic acid chains, under particular reaction conditions, allowed the preparation of gels having the characteristic uncoloured and transparent appearance and high biocompatible and viscoelastic properties.

The products according to the present invention can be prepared in an organic 25 solvent such as dimethylformamide (DMF) and dimethylsulphoxide (DMSO) or in water in the presence of carbodiimide according to a known process (see for example Tomihata, *J. Biomed. Mater. Res.*, 1997, 37(2), 243-251; Danishefsky, *Carbohydrate Res.*, 1971, 16, 199-205).

This reaction is carried out in two subsequent steps: the first step concerns the 30 activation of hyaluronic acid, and the second one the formation of bonds between hyaluronic acid and the cross-linking agent.

During the activation step the carboxylic groups of hyaluronic acid sodium salt

react with an activating compound, thus forming a novel chemical product having an increased electrophilic character of the carboxylic groups.

In the following step a cross-linking agent is added, this agent comprises two nucleophilic functions able to bind the activated carboxylic groups, making thus
5 cross-links, i.e. bridging bonds between the hyaluronic acid molecules. Moreover, the good exiting properties of the activating agent favour the reaction.

The present activating agents are those commonly used in the literature to this aim, and in particular the water soluble carbodiimides; according to the present invention the N-3-dimethylamino-propylethylcarbodiimide hydrochloride is
10 particularly preferred.

According to the present invention the cross-linking agents are bi-functional α L-aminoacids i.e. having a second functional group besides the aminoacidic group - or L-aminoesters or mixtures thereof. Particularly preferred are L-lysine, L-serine, L-lysine ethylester di-hydrochloride and L-serine methylester hydrochloride or
15 mixtures thereof.

The use of aminoesters instead of aminoacids allows the protection of the carboxylic functions of aminoacids in relation to a possible activation and involvement in secondary reactions.

The whole preparation process is carried out as described herein after.

20 The reaction is carried out by using a glass reactor equipped with a stirring system and a temperature controller. The hyaluronic acid sodium salt commercially available is dissolved in water in a concentration comprised between 0.5 and 2.5% (w/w) following to the characteristics in the final product. For example, in order to yield compact and thick gels high concentrations are needed, for example
25 concentrations of 2-2.5%; whereas at concentrations comprised between 0.5 and 1% fluid gels are obtainable.

The temperature is an essential condition to obtain the products of the invention, and it must be comprised between 0°C and 25°C, and preferably between 0°C and 10°C.

30 The reaction mixture is then acidified by adding a diluted acid, such as hydrochloric acid 0.5-1M, until a pH value comprised between 3 and 6, preferably 5, is reached. An activating agent able to activate the carboxylic groups of hyaluronic acid toward

cross-linking, is then added. The activating agent is preferably added in a quantity comprised between 0.2 and 2 equivalents per equivalent of monomeric unit in the starting hyaluronic acid.

In succession the cross-linking agent is added, in a quantity preferably comprised
5 between 0.1 and 2 equivalents per equivalent of monomeric unit of the starting hyaluronic acid.

Following to the additions above, the reaction mixture is maintained under stirring for a time comprised between 5 minutes and 48 hours, and preferably between 15 minutes and 5 hours.

10 Once the reaction is completed, a volume of the solution of NaCl 1M is added, the mixture is maintained under stirring for some minutes, then a purification is carried out according to known methods, such as dialysis and/or precipitation with organic solvent and/or under vacuum evaporation and/or freeze drying.

The reaction may be carried out in an organic solvent, such as DMSO or DMF, or
15 in a mixture water/organic solvent in different ratios; the use of water as the reaction solvent is certainly preferred but, sometimes, it is necessary to use organic solvents for specific applications of the present products.

So the reaction is carried out, by adding in succession a solution in the organic solvent of the activating agent, preferably 2-chloro-1-methylpyridine iodide, and a
20 suspension of the cross-linking aminoacid, to a solution of the hyaluronic acid salt of tetrabutylammonium in the organic solvent or in a mixture of the organic solvent and water, in the presence of triethylamine and under stirring, maintaining the temperature lower than 5°C.

The so obtained mixture is maintained under stirring for a time comprised between
25 5 minutes and 48 hours, and preferably between 15 minutes and 5 hours. The product is then recovered and purified according to the above mentioned methods. The solid product may be dissolved again in water or in physiologic solution, in different concentrations so to obtain viscous solutions, gels, thin films, etc.

In the following examples both preparation procedures are illustrated.

30 The ratios hyaluronic acid/activating agent/cross-linking agent selected for the synthesis depend on the desired cross-linking degree and the viscoelastic characteristics.

The characteristics of the final product are affected by the type of starting hyaluronic acid. As a matter of fact, it is evident that, under the same conditions, a hyaluronic acid having higher molecular weight produces a more viscous and compact gel with respect to that obtainable starting from a hyaluronic acid having a lower molecular weight.

According to a preferred embodiment of the invention, a hyaluronic acid having a molecular weight comprised between 100,000 and 2,000,000 is used, and the final products obtained have a molecular weight comprised between 200,000 and 2,500,000.

The final products show a cross-linking degree comprised between 10 and 40% and an intrinsic viscosity comprised between 300 and 1,500 mg/l.

The activating agent is preferably a carbodiimide soluble in water, in particular the N-3-dimethylamino-propylethylcarbodiimide hydrochloride.

The cross-linking agent is preferably L-lysine or L-serine or esters thereof, preferably ethyl or methyl esters.

The invention will be better understood in view of the following examples.

EXAMPLE 1

1 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 20°C by means of a thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.58 g (1.2 eq) of N-3-dimethylamino-propylethylcarbodiimide hydrochloride and 0.44 g (1.2 eq) of L-lysine are added.

After 2 hours 80 ml of NaCl solution 1M are added, and the solution is dialysed with distilled water; the product is precipitated with acetone, dissolved again in water and finally freeze-dried.

EXAMPLE 2

1 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 20°C by means of a thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.58 g (1.2 eq) of N-3-dimethylamino-propylethylcarbodiimide hydrochloride and 0.74 g (1.2 eq) of L-lysine ethyl ester di-hydrochloride are added.

After 1 hour 80 ml of NaCl solution 1M are added, and the solution is dialysed

three times, and finally freeze-dried.

EXAMPLE 3

1 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 4°C by means of a
5 thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.48 g (1.0 eq) of N-3-dimethylamino-propylethylcarbodiimide hydrochloride and 0.62 g (1.0 eq) of L-lysine ethyl ester di-hydrochloride are added.

After 3 hour 80 ml of NaCl solution 1M are added, and the solution is dialysed three times, and finally freeze-dried.

10 The ¹H-NMR analysis on the so obtained product has shown the following characteristic signals (solvent D₂O):

1.2 ppm (t, 3H, J = 10.6 Hz, CH₃-CH₂CH₂O-Lys)

1.4 ppm (m, 2H, CH₂ δ Lys)

1.6 ppm (m, 2H, CH₂ γ Lys)

15 1.7-1.9 ppm (m, 2H, CH₂ β Lys)

1.9-2.0 ppm (m, 3H, CH₃-CONH hyaluronic acid)

2.9 ppm (t, 2H, J = 11.2 Hz, CH₂ ε Lys)

3.0-3.9 ppm (m, CHOH hyaluronic acid)

4.0 ppm (t, 1H, J = 9.6 Hz, CH α Lys)

20 4.2 ppm (q, 2H, J = 10.6 Hz, CH₃-CH₂O-Lys)

EXAMPLE 4

1.0 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 4°C by means of a thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

25 0.24 g (0.5 eq) of N-3-dimethylamino-propylethylcarbodiimide hydrochloride and 0.62 g (1.0 eq) of L-lysine ethyl ester di-hydrochloride are added.

After 3 hours 80 ml of NaCl solution 1M are added, and the solution is dialysed three times, and finally freeze-dried.

EXAMPLE 5

30 1.0 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 4°C by means of a thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.24 g (0.5 eq) of N-3-dimethylamino-propylethylcarbodiimide hydrochloride and 0.62 g (1.0 eq) of L-lysine ethyl ester di-hydrochloride are added.

After 20 minutes 80 ml of NaCl solution 1M are added, and the solution is dialysed three times, and finally freeze-dried.

5 EXAMPLE 6

1.0 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 20°C by means of a thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.58 g (1.2 eq) of N-3-dimethylamino-propylethylcarbodiimide hydrochloride and
10 0.47 g (1.2 eq) of L-serine methyl ester hydrochloride are added.

After 3 hours 80 ml of NaCl solution 1M are added, and the solution is dialysed with distilled water; the product is then precipitated with acetone, dissolved again in water, and finally freeze-dried.

EXAMPLE 7

15 1.0 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 5°C by means of a thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.47 g (1.0 eq) of N-3-diethylamino-propylethylcarbodiimide hydrochloride and 0.19 g (0.5 eq) of L-serine methyl ester hydrochloride are added.

20 After 3 hours 80 ml of NaCl solution 1M are added, and the solution is dialysed three times, and finally freeze-dried.

EXAMPLE 8

1.0 g of hyaluronic acid sodium salt (2.5 mmol) are dissolved in 80 ml of demineralized water. The temperature is maintained at 0°C by means of a
25 thermostatic bath and the pH value is brought to 5 by addition of HCl 0.75 M.

0.24 g (0.5 eq) of N-3-diethylamino-propylethylcarbodiimide hydrochloride and 0.19 g (0.5 eq) of L-serine methyl ester di-hydrochloride are added.

After 15 minutes 80 ml of NaCl solution 1M are added, and the solution is dialysed three times, and finally freeze-dried.

30 EXAMPLE 9

0.5 g of hyaluronic acid tetrabutylammonium salt are dissolved in 45 ml of DMF, under stirring and at the temperature of 5°C.

Once the salt is completely dissolved, 200 μ l of triethylamine, 0.20 g of 2-chloro-1-methyl-pyridine iodide and 0.5 g of L-lysine are added.

The resulting gel is filtered, washed with water, and freeze-dried.

EXAMPLE 10

- 5 0.3 g of hyaluronic acid tetrabutylammonium salt are dissolved in 30 ml of DMF, under stirring and at the temperature of 5°C.

Once the salt is completely dissolved, 120 ml of triethylamine, 0.12 g of 2-chloro-1-methyl-pyridine iodide and 0.21 g of L-serine are added.

The resulting gel is filtered, washed with water, and freeze-dried.

- 10 Analogously, gels of hyaluronic acid are prepared using as the cross-linking agent mixtures of L-lysine and L-serine, L-lysine ethylester di-hydrochloride and L-serine methylester hydrochloride or mixtures amnoacid/aminoacid esterified, obtaining then products having characteristics analogous to those of the products described above.

CLAIMS

- 1 1. A gel consisting of hyaluronic acid cross-linked with bi-functional cross-linking
2 agents.
- 1 2. The gel according to claim 1, wherein the said bi-functional cross-linking agents
2 are L-aminoacids, L-aminoesters or mixtures thereof.
- 1 3. The gel according to claim 2, wherein the said bi-functional cross-linking agents
2 are L-lysine, L-serine, L-lysine ethylester di-hydrochloride, L-serine methylester
3 hydrochloride or mixtures thereof.
- 1 4. The gel according to claims 1-3, wherein the hyaluronic acid has a molecular
2 weight comprised between 100,000 and 2,500,000 and an intrinsic viscosity
3 comprised between 300 and 1,500 ml/g.
- 1 5. Process for the preparation of the gel as described in claim 1, wherein:
2 a) the hyaluronic acid sodium salt is dissolved in water under stirring and the
3 reaction mixture is then acidified by adding a diluted acid, until a pH value
4 comprised between 3 and 6 is reached;
5 b) an activating agent and then a cross-linking agent are added to the solution
6 under stirring;
7 c) once the reaction is completed, to the resulting mixture a solution of NaCl 1 M is
8 added under stirring, then the separation and purification procedure of the so
9 obtained product is carried out.
- 1 6. The process according to claim 5, wherein the temperature is comprised
2 between 0°C and 25°C.
- 1 7. The process according to claim 6, wherein the temperature is comprised
2 between 0°C and 10°C.
- 1 8. The process according to claims 5-7, wherein the activating agent is a
2 carbodiimide soluble in water.
- 1 9. The process according to claim 8, wherein the activating agent is N-3-
2 dimethylamino-propylethylcarbodiimide hydrochloride.
- 1 10. The process according to claim 5-9, wherein the cross-linking agent is an
2 aminoacid as reported in claims 2 and 3.
- 1 11. The process according to claims 5-10, wherein the hyaluronic acid solution in
2 water has a concentration comprised between 0.5 and 2.5% (w/w), the activating

3 agent is added in a quantity comprised between 0.2 and 2 equivalents per
4 equivalent of monomeric unit of hyaluronic acid, and the cross-linking agent is
5 added in a quantity comprised between 0.1 and 2 equivalents per equivalent of
6 monomeric unit of hyaluronic acid.

1 12. The process according to claim 11, wherein the time of reaction is comprised
2 between 5 minutes and 48 hours.

1 13. The process according to claim 12, wherein the time of reaction is comprised
2 between 15 minutes and 5 hours.

1 14. Use of the gel as described in claims 1-4 in surgery, in the pharmacological
2 field or, in general, in the biomedical field.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/01239

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C08B37/08 A61K9/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, COMPENDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 760 200 A (MILLER ROBERT J ET AL) 2 June 1998 (1998-06-02) column 8, line 14-47; claim 6; examples 11,17,23 column 15, line 41-67 --- -/--	1-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 June 2001

Date of mailing of the international search report

29/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Radke, M

INTERNATIONAL SEARCH REPORT

In* national Application No

PCT/EP 01/01239

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TOMIHATA K ET AL: "CROSSLINKING OF HYALURONIC ACID WITH WATER-SOLUBLE CARBODIIMIDE"</p> <p>JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, vol. 37, no. 2, November 1997 (1997-11), pages 243-251, XP000965636</p> <p>ISSN: 0021-9304</p> <p>cited in the application</p> <p>*Pages 247 - 248; para. "Crosslinking of HA in the presence of L-lysine and its methyl ester"; page 250, reaction scheme (5); page 243, 1st par. of the INTRODUCTION; and the abstract* page 244</p> <p>---</p>	1-3, 14
X	<p>JP 07 102002 A (GUNZE LTD; OTHERS: 01)</p> <p>18 April 1995 (1995-04-18)</p> <p>*paragraphs '0001!', '0009!' and '0013!*</p> <p>examples 1-3, 8</p> <p>---</p>	1-4, 14
A	<p>US 5 856 299 A (BELLINI DAVIDE ET AL)</p> <p>5 January 1999 (1999-01-05)</p> <p>examples 21, 22</p> <p>---</p>	
A	<p>BULPITT P ET AL: "NEW STRATEGY FOR CHEMICAL MODIFICATION OF HYALURONIC ACID: PREPARATION OF FUNCTIONALIZED DERIVATIVES AND THEIR USE IN THE FORMATION OF NOVEL BIOCOMPATIBLE HYDROGELS"</p> <p>JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, vol. 47, no. 2, 1999, pages 152-169, XP000913609</p> <p>ISSN: 0021-9304</p> <p>page 155; figure 2</p> <p>page 161, left-hand column</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/01239

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5760200 A	02-06-1998	US 6174999 B	16-01-2001
		US 5017229 A	24-05-1991
		US 4937270 A	26-06-1990
		AU 670030 B	04-07-1996
		AU 2143492 A	30-12-1992
		AU 5226796 A	01-08-1996
		EP 0587715 A	23-03-1994
		JP 6508169 T	14-09-1994
		WO 9220349 A	26-11-1992
		US 6030958 A	29-02-2000
		US 5527893 A	18-06-1996
		AT 151294 T	15-04-1997
		AU 660282 B	22-06-1995
		AU 8392491 A	23-01-1992
		DE 69125609 D	15-05-1997
		DE 69125609 T	17-07-1997
		DK 537292 T	04-08-1997
		EP 0537292 A	21-04-1993
		ES 2100954 T	01-07-1997
		FI 925802 A	21-12-1992
		GR 3023436 T	29-08-1997
		NO 924875 A	16-12-1992
		WO 9200105 A	09-01-1992
		US 6235726 B	22-05-2001
		AT 138940 T	15-06-1996
		AU 606230 B	31-01-1991
		AU 2482588 A	17-04-1989
		CA 1332235 A	04-10-1994
		DE 3855351 D	11-07-1996
		DE 3855351 T	10-10-1996
		DK 68990 A	17-05-1990
		EP 0397652 A	22-11-1990
		FI 94357 B	15-05-1995
		JP 2670996 B	29-10-1997
		JP 9183804 A	15-07-1997
		JP 2684208 B	03-12-1997
		JP 3502704 T	20-06-1991
		NO 301770 B	08-12-1997
		NO 942763 A	16-03-1990
		WO 8902445 A	23-03-1989
JP 07102002 A	18-04-1995	NONE	
US 5856299 A	05-01-1999	IT PD940043 A	11-09-1995
		DE 69513507 D	30-12-1999
		DE 69513507 T	06-07-2000
		DK 749446 T	08-05-2000
		EP 0749446 A	27-12-1996
		GR 3032589 T	31-05-2000
		AT 186916 T	15-12-1999
		CA 2184899 A	14-08-1995
		WO 9524429 A	14-09-1995
		ES 2141925 T	01-04-2000
		PT 749446 T	31-05-2000